Teladoc Health Q3 2024 GAAP EPS $(0.19) Beats $(0.27) Estimate, Sales $640.508M Beat $631.160M Estimate
Portfolio Pulse from Benzinga Newsdesk
Teladoc Health reported Q3 2024 earnings with a GAAP EPS of $(0.19), beating the estimate of $(0.27). Sales were $640.508M, surpassing the $631.160M estimate but showing a 2.99% decrease from last year.
October 30, 2024 | 9:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Teladoc Health's Q3 2024 earnings report shows a better-than-expected EPS of $(0.19) and sales of $640.508M, beating estimates but reflecting a year-over-year sales decline.
Teladoc Health's earnings beat expectations, which is typically positive for stock prices. However, the year-over-year sales decline may temper investor enthusiasm. Overall, the positive earnings surprise is likely to have a short-term positive impact on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100